Two consumers filed a class-action lawsuit claiming pharmaceutical giants GlaxoSmithKline (GSK) and Sanofi (SNY), among others, failed to warn consumers that the heartburn medication, Zantac, produces a clinically proven carcinogen in the body at levels far beyond what regulators consider safe.
According to Beth Fegan, founder and managing member of consumer-rights law firm FeganScott, Zantac and its generic active ingredient, ranitidine, became one of the world’s best-selling drugs through a massive advertising campaign that touted the drug as safe.
“Now we know those claims are wrong, and we intend to show that the defendants knew this but continued to advocate the drug’s safety in the face of abundant evidence to the contrary,” said Fegan.
Read the full article here.